Author(s)

Kazim Erol, Esin Sogutlu Sari, Arif Koytak, A Karaçor, D. T. Çoban, M. Bulut

Antalya Training and Research Hospital, Ophthalmology Department, Antalya, Turkey.
Bezmialem Vak?f University, Ophthalmology Department, Istanbul, Turkey.
Kartal Training and Research Hospital, Ophthalmology Department, Istanbul, Turkey.

Purpose: The author report the result of three consecutive monthly intravitreal ranibizumab injection for choroidal neovascularization (CNV) after bevacizumab injection for chronic central serous rethinopathy (CSR). Methods: A 48 year old man with chronic CSR was treated with intravitreal single dose 2.5 mg bevacizumab. One year after CNV was occurred, and three consecutive monthly intravitreal ranibizumab injections were performed. Results: Four weeks later the first ranibizumab dose, best corrected visual acuity was improved 20/80 to 20/20 and remained stable within one year. Conclusion: Repeat intravitreal ranibizumab injection in CNV after bevacizumab injection for chronic CSR appeared to be an effective treatment option.

Central Serous Choriorethinopathy; Choroidal Neovascularization; Ranibizumab

K. Erol, E. Sogutlu Sari, A. Koytak, A. Karaçor, D. T. Çoban and M. Bulut, "Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Choriorethinopathy: A Case Report," Open Journal of Ophthalmology, Vol. 2 No. 3, 2012, pp. 93-96. doi: 10.4236/ojoph.2012.23020.